ADM Korea Inc.

Equities

A187660

KR7187660006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
3,310 ^KRW	+0.61%		-3.07%	+70.79%

May. 20	Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..	CI
Mar. 11	Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	CI

Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.

October 24, 2022 at 12:21 am EDT

From April 22, 2022 to June 30, 2022, the company has repurchased 560,879 shares, representing 2.57% for KRW 2,373.37 million. With this, the company has completed the repurchase of 560,879 shares, representing 2.57% for KRW 2,373.37 million under the buyback announced on April 22, 2022.

Latest news about ADM Korea Inc.

Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..	May. 19	CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	Mar. 10	CI
ADM Korea Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.	22-10-24	CI
Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.	22-10-24	CI
Tranche Update on ADM Korea Inc.'s Equity Buyback Plan announced on April 22, 2022.	22-10-24	CI
ADM Korea Inc.'s Equity Buyback announced on April 22, 2022, has expired with 683,321 shares, representing 3.13% for KRW 2,737.04 million.	22-10-20	CI
ADM Korea Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	22-04-22	CI
ADM Korea Inc. authorizes a Buyback Plan.	22-04-21	CI
ADM Korea Inc. announced that it has received KRW 9.9999584 billion in funding from Hanyang Securities Co. Ltd., Mirae Asset Securities Co., Ltd.	22-04-19	CI
ADM Korea Inc. announced that it expects to receive KRW 9.9999584 billion in funding from Hanyang Securities Co. Ltd., Mirae Asset Securities Co., Ltd. and other investors	22-04-11	CI
ADM Korea Inc. announced that it has received KRW 5.9990385 billion in funding from Industrial Bank of Korea	19-04-29	CI
ADM Korea Inc. announced that it expects to receive KRW 5.9990385 billion in funding from Industrial Bank of Korea	19-04-28	CI
Mobiis Co., Ltd. completed the acquisition of 43.9% stake in ADM Korea Inc. from Mihyun Cho.	19-01-13	CI
Mobiis Co., Ltd. agreed to acquire 43.9% stake in ADM Korea Inc. from Mihyun Cho for KRW 8.8 billion.	18-12-13	CI
Seokmin Yoon, President, Chief Executive Officer and representative Director of ADM Korea Inc. cancelled the acquisition of 25.1% stake in ADM Korea Inc. from EPS International Co., Ltd.	12-03-28	CI

Chart ADM Korea Inc.

Duration

Period

More charts

Company Profile

ADM Korea Inc is a Korea-based company primarily engaged in the provision of clinical trial services. The Company is a contract research organization (CRO) that provides clinical trial related services to pharmaceutical companies and bio ventures. The Company also provides post-marketing research (rPMS) services.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADM KOREA INC.	+70.79%	50.63M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research